269 related articles for article (PubMed ID: 26925841)
1. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE
BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841
[TBL] [Abstract][Full Text] [Related]
2. Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
Sakakibara K; Tsujioka T; Kida JI; Kurozumi N; Nakahara T; Suemori SI; Kitanaka A; Arao Y; Tohyama K
Int J Hematol; 2019 Aug; 110(2):213-227. PubMed ID: 31129802
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma.
Hart LS; Rader J; Raman P; Batra V; Russell MR; Tsang M; Gagliardi M; Chen L; Martinez D; Li Y; Wood A; Kim S; Parasuraman S; Delach S; Cole KA; Krupa S; Boehm M; Peters M; Caponigro G; Maris JM
Clin Cancer Res; 2017 Apr; 23(7):1785-1796. PubMed ID: 27729458
[No Abstract] [Full Text] [Related]
4. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Zhang L; Scorsone K; Woodfield SE; Zage PE
Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
[TBL] [Abstract][Full Text] [Related]
6. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
7. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
8. High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
Cai J; Jacob S; Kurupi R; Dalton KM; Coon C; Greninger P; Egan RK; Stein GT; Murchie E; McClanaghan J; Adachi Y; Hirade K; Dozmorov M; Glod J; Boikos SA; Ebi H; Hao H; Caponigro G; Benes CH; Faber AC
Cell Rep; 2022 Jul; 40(4):111095. PubMed ID: 35905710
[TBL] [Abstract][Full Text] [Related]
9. MEK inhibitors as a novel therapy for neuroblastoma: Their in vitro effects and predicting their efficacy.
Tanaka T; Higashi M; Kimura K; Wakao J; Fumino S; Iehara T; Hosoi H; Sakai T; Tajiri T
J Pediatr Surg; 2016 Dec; 51(12):2074-2079. PubMed ID: 27686482
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.
Ahsan S; Ge Y; Tainsky MA
Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
[TBL] [Abstract][Full Text] [Related]
12. Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
Nguyen NT; Raetz A; Montoya D; Schilling V; Tong C; Brooks RA; Leiserowitz G; Chien J
Gynecol Oncol; 2023 Nov; 178():69-79. PubMed ID: 37806229
[TBL] [Abstract][Full Text] [Related]
13. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.
See WL; Tan IL; Mukherjee J; Nicolaides T; Pieper RO
Cancer Res; 2012 Jul; 72(13):3350-9. PubMed ID: 22573716
[TBL] [Abstract][Full Text] [Related]
15. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
Hölzel M; Huang S; Koster J; Ora I; Lakeman A; Caron H; Nijkamp W; Xie J; Callens T; Asgharzadeh S; Seeger RC; Messiaen L; Versteeg R; Bernards R
Cell; 2010 Jul; 142(2):218-29. PubMed ID: 20655465
[TBL] [Abstract][Full Text] [Related]
16. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
Breunig C; Mueller BJ; Umansky L; Wahl K; Hoffmann K; Lehner F; Manns MP; Bantel H; Falk CS
Clin Cancer Res; 2014 May; 20(9):2410-23. PubMed ID: 24573550
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
Oh YT; Deng J; Yue P; Owonikoko TK; Khuri FR; Sun SY
Oncogene; 2016 Jan; 35(4):459-67. PubMed ID: 25867065
[TBL] [Abstract][Full Text] [Related]
18. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.
Maiti A; Naqvi K; Kadia TM; Borthakur G; Takahashi K; Bose P; Daver NG; Patel A; Alvarado Y; Ohanian M; DiNardo CD; Cortes JE; Jabbour EJ; Garcia-Manero G; Kantarjian HM; Ravandi F
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):142-148.e1. PubMed ID: 30635233
[TBL] [Abstract][Full Text] [Related]
19. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
20. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]